Skip to search formSkip to main contentSkip to account menu

Cyclophosphamide

Known as: CPM, 2H-1,3,2-oxazaphosphorin-2-amine, N,N-is(2-chloroethyl)tetrahydro-,2-oxide, N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide 
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active… 
National Institutes of Health

Related topics

Related topics

47 relations

Narrower (16)

4-methylcyclophosphamideACP protocolCEOP-B protocolCHOP protocol-cyclophosphamide/doxorubicin/prednisone/vincristine
Expand
CEV regimenCFP protocolCMF-B protocolCMFVP protocol
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
The Microbiota Makes for Good Therapy The gut microbiota has been implicated in the development of some cancers, such as… 
Highly Cited
2010
Highly Cited
2010
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
BACKGROUND Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe… 
Highly Cited
2006
Highly Cited
2006
Cyclophosphamide versus placebo in scleroderma lung disease.
BACKGROUND We conducted a double-blind, randomized, placebo-controlled trial to determine the effects of oral cyclophosphamide on… 
Review
2005
Review
2005
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Review
2005
Review
2005
Extended-Spectrum β-Lactamases: a Clinical Update
SUMMARY Extended-spectrum β-lactamases (ESBLs) are a rapidly evolving group of β-lactamases which share the ability to hydrolyze… 
Highly Cited
2001
Highly Cited
2001
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
BACKGROUND The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30… 
Review
1998
Review
1998
Polychemotherapy for early breast cancer: an overview of the randomised trials
Highly Cited
1996
Highly Cited
1996
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
BACKGROUND Intravenous platinum-based chemotherapy is the standard primary therapy for advanced ovarian cancer. We conducted a… 
Highly Cited
1996
Highly Cited
1996
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
BACKGROUND Chemotherapy combinations that include an alkylating agent and a platinum coordination complex have high response… 
Highly Cited
1947
Highly Cited
1947
DISEASE
  • 1947
  • Corpus ID: 222064452
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License